Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression

Journal of Affective Disorders

Volumn 172, Issue , 2015, Pages 307-311

  Ortiz, Robin ^a   Niciu, Mark J ^a   Lukkahati, Nada ^b,c   Saligan, Leorey N ^b   Nugent, Allison C ^a   Luckenbaugh, David A ^a   Machado Vieira, Rodrigo ^a   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

^c UNIVERSITY OF NEVADA   (United States)

Author keywords

Bipolar depression; Ketamine; MRI; PET; Shank3

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GLUCOSE; KETAMINE; PEPTIDES AND PROTEINS; PROTEIN SHANK3; UNCLASSIFIED DRUG; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYLASPARTIC ACID;

ADULT; AGED; AMYGDALOID NUCLEUS; ARTICLE; BIPOLAR DEPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; AMYGDALA; BIPOLAR DISORDER; BLOOD; FEMALE; MALE; METABOLISM; TREATMENT OUTCOME;

ADULT; AGED; AMYGDALA; ANTIDEPRESSIVE AGENTS; BIOMARKERS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KETAMINE; MALE; N-METHYLASPARTATE; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 84908425862     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.09.015     Document Type: Article

References (25)

1. M.E. Bringas, F.N. Carvajal-Flores, T.A. Lopez-Ramirez, M. Atzori, and G. Flores Rearrangement of the dendritic morphology in limbic regions and altered exploratory behavior in a rat model of autism spectrum disorder Neuroscience 241 2013 170 187
2. M.N. Davies, M. Volta, R. Pidsley, K. Lunnon, A. Dixit, S. Lovestone, C. Coarfa, R.A. Harris, A. Milosavljevic, C. Troakes, S. Al-Sarraj, R. Dobson, L.C. Schalkwyk, and J. Mill Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood Genome Biol. 13 2012 R43
3. J.F. Deakin, J. Lees, S. McKie, J.E. Hallak, S.R. Williams, and S.M. Dursun Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study Arch. Gen. Psychiatry 65 2008 154 164
4. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, S. Khalife, W.A. Kammerer, Z. Quezado, D.A. Luckenbaugh, G. Salvadore, R. Machado-Vieira, H.K. Manji, and C.A. Zarate Jr. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression Arch. Gen. Psychiatry 67 2010 793 802
5. R.S. Duman Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections Dialogues Clin. Neurosci. 16 2014 11 27
6. A. Guilmatre, G. Huguet, R. Delorme, and T. Bourgeron The emerging role of SHANK genes in neuropsychiatric disorders Dev. Neurobiol. 74 2014 113 122
7. K. Han, J.L. Holder Jr., C.P. Schaaf, H. Lu, H. Chen, H. Kang, J. Tang, Z. Wu, S. Hao, S.W. Cheung, P. Yu, H. Sun, A.M. Breman, A. Patel, H.-C. Lu, and H.Y. Zoghbi SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties Nature 503 2013 72 77
8. M. Kouser, H.E. Speed, C.M. Dewey, J.M. Reimers, A.J. Widman, N. Gupta, S. Liu, T.C. Jaramillo, M. Bangash, B. Xiao, P.F. Worley, and C.M. Powell Loss of predominant shank3 isoforms results in hippocampus-dependent impairments in behavior and synaptic transmission J. Neurosci. 33 2013 18448 18468
9. P.C.W. Lee, J.-C. Dodart, L. Aron, L.W. Finley, R.T. Bronson, M.C. Haigis, B.A. Yanker, and J.W. Harper Altered social behavior and neuronal development in mice lack the Uba6-Use1 ubiquitin transfer system Molecular Cell 50 2013 172 184
10. P. Licznerski, and R.S. Duman Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression Neuroscience 251 2013 33 50
11. M.J. Niciu, D.C. Mathews, A.C. Nugent, D.F. Ionescu, M.L. Furey, E.M. Richards, R. Machado-Vieira, and C.A. Zarate Jr. Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants Depress. Anxiety 31 2014 297 307
12. A.C. Nugent, R.M. Davis, C.A. Zarate Jr., and W.C. Drevets Reduced thalamic volumes in major depressive disorder Psychiatry Res. 213 2013 179 185
13. A.C. Nugent, N. Diazgranados, P.J. Carlson, L. Ibrahim, D.A. Luckenbaugh, N. Brutsche, P. Herscovitch, W.C. Drevets, and C.A. Zarate Jr. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder Bipolar Disord. 16 2014 119 128
14. A.C. Nugent, D.A. Luckenbaugh, S.E. Wood, W. Bogers, C.A. Zarate Jr., and W.C. Drevets Automated subcortical segmentation using FIRST: test-retest reliability, interscanner reliability, and comparison to manual segmentation Hum. Brain Mapp. 34 2013 2313 2329
15. J. Peca, C. Feliciano, J.T. Ting, W. Wang, M.F. Wells, T.N. Venkatraman, C.D. Lascola, Z. Fu, and G. Feng Shank3 mutant mice display autistic-like behaviours and striatal dysfunction Nature 472 2011 437 442
16. A.G. Pillai, D. de Jong, S. Kanatsou, H. Krugers, A. Knapman, J.M. Heinzmann, F. Holsboer, R. Landgraf, M. Joels, and C. Touma Dendritic morphology of hippocampal and amygdalar neurons in adolescent mice is resilient to genetic differences in stress reactivity PloS One 7 2012 e38971
17. M. Raab, T.M. Boeckers, and W.L. Neuhuber Proline-rich synapse-associated protein-1 and 2 (ProSAP1/Shank2 and ProSAP2/Shank3)-scaffolding proteins are also present in postsynaptic specializations of the peripheral nervous system Neuroscience 171 2010 421 433
18. G. Roussignol, F. Ango, S. Romorini, J.C. Tu, C. Sala, P.F. Worley, J. Bockaert, and L. Fagni Shank expression is sufficient to induce functional dendritic spine synapses in spiny neurons J. Neurosci. 25 2005 3560 3570
19. G. Serafini Neuroplasticity and major depression, the role of modern antidepressant drugs World J. Psychiatry 2 2012 49 57
20. Y.I. Sheline, M.H. Gado, and H.C. Kraemer Untreated depression and hippocampal volume loss Am. J. Psychiatry 160 2003 1516 1518
21. J. Shen, K.F. Petersen, K.L. Behar, P. Brown, T.W. Nixon, G.F. Mason, O.A. Petroff, G.I. Shulman, R.G. Shulman, and D.L. Rothman Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR Proc. Natl. Acad. Sci. USA 96 1999 8235 8240
22. K. Vassilopoulou, M. Papathanasiou, I. Michopoulos, F. Boufidou, P. Oulis, N. Kelekis, E. Rizos, C. Nikolaou, C. Pantelis, D. Velakoulis, and L. Lykouras A magnetic resonance imaging study of hippocampal, amygdala and subgenual prefrontal cortex volumes in major depression subtypes: melancholic versus psychotic depression J. Affect. Disord. 146 2013 197 204
23. C.A. Zarate Jr., N.E. Brutsche, L. Ibrahim, J. Franco-Chaves, N. Diazgranados, A. Cravchik, J. Selter, C.A. Marquardt, V. Liberty, and D.A. Luckenbaugh Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial Biol. Psychiatry 71 2012 939 946
24. C.A. Zarate Jr., J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh, D.S. Charney, and H.K. Manji A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 2006 856 864
25. L. Zhang, C.T. Li, T.P. Su, X.Z. Hu, R.A. Lanius, M.J. Webster, M.Y. Chung, Y.S. Chen, Y.M. Bai, J.L. Barker, J.E. Barrett, X.X. Li, H. Li, D.M. Benedek, and R. Ursano P11 expression and PET in bipolar disorders J. Psychiatr Res. 45 2011 1426 1431